Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases, including cardiovascular and autoimmune diseases. A-002 and A-001 inhibit a novel enzyme target known as secretory phospholipase A2. Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as coronary artery disease. A-623 targets elevated levels BLyS, which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus and others.

Contact Information

25801 Industrial Blvd, Suite B
Hayward, CA 94545

tel: (510) 856–5600
fax: (510) 856–5597


Investor Relations




Exchange: NASDAQ
Industry: Pharmaceutical Manufacturer and Distributor
Market Cap: $100M

The information provided here has been obtained from publicly available sources as well as directly from issuers in some cases. Please see our Disclaimer and Terms of Service for more information.